After consenting to the study, participants were assigned a unique and de-identified Participant ID. Participants were asked to enter the ID at the beginning of each assessment they completed for the duration of the study, and to protect the confidentiality of the participants these IDs were the only means of linking their data over time and across assessments. Further, to ensure anonymization, the Participant IDs have been replaced with numeric placeholders in the publicly available datasets. Study data were collected and managed using REDCap13,14 electronic data capture tools hosted at Boston College. REDCap is a secure, web-based software platform designed to support data capture for research studies. Along with their Participant ID, participants received a link to our initial demographic survey. After completion of the demographic survey, participants were placed in the pipeline to receive information on the rest of the assessments as described below for the duration of the study or until they requested to withdraw (<5%). PDF copies of all survey questions are available with the data on the OSF study page: 10.17605/OSF.IO/GPXWA.

Following the consent protocol, participants received an email with their Participant ID and a link to the initial demographic survey. Participants were required to complete this demographic survey prior to receiving information on any further assessments. Participants were asked to report age, race and ethnicity, natal sex, gender identity, sexual orientation, socioeconomic and military status, education, marital status, number of dependents, and previous diagnoses of serious medical and mental health conditions. Further demographic data was collected in the Round 3 one-time assessment (see below).

After completion of the initial Demographic Survey, participants were enrolled to begin receiving our daily survey assessment. To reduce participant burden, two versions of our daily survey were utilized during the assessment period: the Short Version and the Full Version. To establish a baseline of all metrics included in the daily surveys, participants received the Full Survey for at least three days following completion of the demographic survey. The Full Survey was then sent to all participants on randomly selected days 2 days/week, with the Short Survey sent the remaining 5 days/week. To enhance the quality of the data reported, participants were instructed not to try to make up surveys on days that they missed. The Short and Full Version of the daily surveys are described in detail below.

The Short Version of our daily survey included several questions relevant to the duration and quality of sleep, including bedtime, sleep attempt time, sleep latency, time spent awake after sleep onset, morning wake time, and the time participants got out of bed. We also collected daily dream reports, descriptions of activity and exercise, time spent virtually socializing, alcohol consumption, quarantine status, COVID-19 symptoms and diagnosis, and their subjective experience of overall stress. All questions within the Short Version of the survey were optional and participants were asked to respond to any that they were able to given their time and energy that day.

The Full Version of the survey included all questions from the Short Version, as well as questions related to their experience of worry on factors related to COVID-19 (i.e., individual health, health of family, friends, and community, public health, and financial impact), perception of social isolation, current mood using the Positive and Negative Affect Schedule (PANAS)15, and symptoms of depression using a modified version of the Patient Health Questionnaire-9 (PHQ-9)16 that omitted the question assessing suicidality. Most questions within the Full Version were required in order to be submitted, but participation was optional each day it was received.

Participants received either the Short or Full Version of the daily survey at 08:00 in their local time zone every day of the assessment period from March 21, 2020 - May 20, 2020. After May 20th, we discontinued the Short Version of the survey, but continued to send the Full Version of the survey 2 days/week from May 21, 2020 - June 23, 2020. Participants that enrolled in the study after June 23, 2020 only received the Full Version of the survey for the initial three days following completion of the demographic survey.

The Round 1 one-time assessment was launched on May 19, 2020. Initial invitations and reminders to complete the survey were sent via REDCap and email. The Round 1 assessment included the following previously validated measures: Pittsburgh Sleep Quality Index (PSQI)17, pre- and post-COVID assessment of the ultra-short Munich Chronotype Questionnaire18, Generalized Anxiety Disorder (GAD-7) Scale19, Cognitive emotion regulation questionnaire (short version)20, pre- and post-COVID assessment of the Liebowitz Social Anxiety Scale21, and a Big 5 Inventory-2 (Short Form)022.

The Round 2 one-time assessment was launched on June 16, 2020. Initial invitations and reminders to complete the survey were sent via REDCap and email. The Round 2 assessment included the following measures: Insomnia Severity Index (ISI)23, Reduced Morningness Eveningness Questionnaire (RMEQ)24, Perceived Stress Scale25, Toronto Empathy Questionnaire26, and a series of questions specifically tailored for events surrounding the COVID19 pandemic. As part of these questions, we asked participants to reflect on their experience and memory of the onset of the pandemic from March - June, 2020 and to recount specific memories from this time-period and to report their general experience of how positive or negative they remember this period of time being. We also ask them to discuss how well their experience matched their initial predictions about the spread of the pandemic and assessed their future predictions for the success of an eventual reintegration process.

The Round 3 one-time assessment was launched on June 29, 2020. Initial invitations and reminders to complete the survey were sent via email only. The Round 3 assessment included the following measures: Short Urgency-Premeditation-Perseverance-Sensation Seeking-Positive Urgency (UPPS-P) Impulsive Behavior Scale27, Intolerance of Uncertainty Scale28, Emotion Regulation Questionnaire29, Brief Self-Control Scale30, and an Exit Survey collecting additional important demographic information that became apparent over the course of the assessment period and their experience as participants in the study. This included a more detailed assessment of pre-existing and current medical and mental health information, COVID-19 high risk factors, purchasing and use of personal protection equipment (PPE), information on essential workers and healthcare professionals, additional economic impacts of COVID19, implementation of stay-at-home orders or other government-ordered measures initiated in their area, and additional assessment of experience with COVID-related dreaming.

All participants had the opportunity to complete the one-time assessments from their initial launch date until August 26th, 2020. Approximately 55% of the participants completed the first one-time assessment, and approximately 42% of participants completed the Round 2 and Round 3 assessments. Of the total sample, 37.2% (n = 564) completed at least one daily survey and all three rounds of the one-time assessments. The full timeline of the study can be found in Fig. 1.

Schematic of study timeline. IRB approval and study launch occurred on March 20, 2020. Initial enrollment in the study was open until August 5, 2020. Daily survey assessments (a mix of the Full and Short Versions) took place from March 21, 2020 - May 20, 2020. The Full Version assessments then continued 2 days/week from May 21, 2020 - June 23, 2020. The one-time assessments were then released on the following dates: Round 1 – May 19, 2020; Round 2 - June 16, 2020; Round 3 – June 29, 2020.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.